Kim Theilgaard-Mönch
11PUBLICATIONS
61CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Dec 17, 2025
The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.Joana Mujollari, Montserrat Estruch, Priya Khadgawat
|Aug 21, 2025
Mapping early human blood cell differentiation using single-cell proteomics and transcriptomics.Benjamin Furtwängler, Nil Üresin, Sabrina Richter
|Oct 16, 2023
Dose-reduction trials in oncology - aiming for less toxicity and better quality of life at lower costs.Kim Theilgaard-Mönch, Lars Holger Ehlers
|Jun 23, 2022
Transcription factor-driven coordination of cell cycle exit and lineage-specification in vivo during granulocytic differentiation : In memoriam Professor Niels Borregaard.Kim Theilgaard-Mönch, Sachin Pundhir, Kristian Reckzeh
|Mar 21, 2022
Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.Anamarija Pfeiffer, Giulia Franciosa, Marie Locard-Paulet
|Mar 05, 2022
Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML.Anders Centio, Montserrat Estruch, Kristian Reckzeh
Pageof 2
Frequent Collaborators
5 joint publications
Kristian Reckzeh
5 joint publications
Montserrat Estruch Alrich
4 joint publications
Bo T Porse
3 joint publications
Kristen Grønbæk
2 joint publications
Erwin Schoof
2 joint publications
Sophia Engelhard
2 joint publications
Benjamin Furtwängler
2 joint publications
Ulrika Warpman Berglund
1 joint publications
Nicolas Rapin
1 joint publications
Dietmar Vestweber
